Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $29
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $34 to $29.
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $34 to $29.